DEVELOPMENT OF A MODEL TO ASSESS THE COST-EFFECTIVENESS OF THERAPIES FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOLLOWING A REFERENCE MODEL FRAMEWORK
Author(s)
Aguiar-Ibáñez R1, Palencia R2, Kandaswamy P3, Flavin J4, Gauthier A5, Davies MJ6
1Amaris Consulting UK, London, UK, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 3Boehringer Ingelheim UK, Bracknell, UK, 4Boehringer Ingelheim Canada Ltd, Burlingon, ON, Canada, 5Amaris, London, UK, 6University of Leicester, Leicester, UK
OBJECTIVES: To describe the practical approach implemented to construct a global cost-effectiveness model for T2DM therapies following a framework proposed for the development of reference models to inform public funding decisions. METHODS:
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PRM107
Topic
Methodological & Statistical Research
Topic Subcategory
Modeling and simulation
Disease
Diabetes/Endocrine/Metabolic Disorders